[144] Roivant Sciences Ltd. SEC Filing

Rhea-AI Filing Summary

Roivant Sciences Ltd. (ROIV) filed a Form 144 disclosing a proposed sale of 355,161 common shares by a covered person through Rockefeller Financial LLC on 10/07/2025, with an aggregate market value of $5,734,289.35 and 682,881,743 shares outstanding. The filing shows those shares were acquired on 10/07/2025 by exercise of stock options granted on 03/26/2020, 11/20/2017, and 04/20/2022, with 67,171, 107,131, and 180,859 shares from each grant respectively, and payment by wire.

The form also lists multiple sales by Eric Venker in the prior three months totaling over 1.99 million shares across trades between 07/21/2025 and 10/06/2025 with gross proceeds exceeding $31M (sum of reported proceeds). The filer certifies no undisclosed material adverse information and follows the Rule 144 disclosure requirements.

Positive

• Full Rule 144 disclosure filed showing grant dates, acquisition method, and broker
• Specific trade dates and gross proceeds listed for multiple prior sales, increasing transparency

Negative

• Large recent insider sales: over 1.99M shares sold across July–October 2025 with reported gross proceeds in excess of $31M
• Near-term additional supply: proposed sale of 355,161 shares on 10/07/2025 could add selling pressure

Insights

Securities Compliance Analyst

TL;DR: The filing documents a routine Rule 144 sale after option exercises, with multiple recent insider dispositions disclosed.

The notice identifies a proposed sale of 355,161 shares acquired by option exercise on 10/07/2025, listing grant dates and share counts for each exercise. This follows several sales by the same person in the prior three months, which are itemized with exact dates and gross proceeds. The structure and content match Rule 144 disclosure elements required for resale by affiliates.

Key dependencies are accurate trade execution and broker reporting; any deviation from planned sale dates or contradictory public disclosures would warrant follow-up. Monitor reported transaction settlement and any subsequent amendments within days after execution.

Equity Markets Specialist

TL;DR: Insider liquidity appears substantial over the past quarter, potentially increasing share supply near disclosed dates.

Recent documented sales show large volumes: individual trades of 683,818 and 611,000 shares and multiple smaller trades between 07/21/2025 and 10/06/2025, producing reported gross proceeds in the millions. The proposed sale of 355,161 shares on 10/07/2025 would add to this near-term supply.

The primary risk is short-term share supply pressure around the listed sale dates; watch trading volumes and price impact on and immediately after 10/07/2025.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Rockefeller Financial LLC 45 Rockefeller Plaza Floor 5 New York NY 10111	355161	5734289.35	682881743	10/07/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Shares	10/07/2025	Options Exercise - Grant Date 03/26/2020	Roivant Sciences Ltd.			67171	10/07/2025	Wire
Common	10/07/2025	Options Exercise - Grant Date 11/20/2017	Roivant Sciences Ltd.			107131	10/07/2025	Wire
Common	10/07/2025	Options Exercise - Grant Date 04/20/2022	Roivant Sciences Ltd.			180859	10/07/2025	Wire

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Eric Venker c/o Roivant Sciences LTD 7th Floor, 50 Broadway, London X0 SW1HODB	Common shares	08/20/2025	100000	1172120.12
Eric Venker c/o Roivant Sciences LTD 7th Floor, 50 Broadway,, London X0 SW1HODB	Common Shares	07/21/2025	100000	1151941.91
Eric Venker c/o Roivant Sciences LTD 7th Floor, 50 Broadway,, London X0 SW1HODB	Common Shares	09/19/2025	683818	10220412.21
Eric Venker c/o Roivant Sciences LTD 7th Floor, 50 Broadway London X0 SW1HODB	Common Shares	09/22/2025	316182	4741054.24
Eric Venker c/o Roivant Sciences LTD 7th Floor, 50 Broadway, London X0 SW1HODB	Common Shares	09/22/2025	100000	1501338.85
Eric Venker c/o Roivant Sciences LTD 7th Floor, 50 Broadway, London X0 SW1HODB	Common Shares	09/23/2025	611000	9061130.00
Eric Venker c/o Roivant Sciences LTD 7th Floor, 50 Broadway,, London X0 SW1HODB	Common Shares	10/06/2025	171396	2800364.71

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the Form 144 filed by Roivant Sciences (ROIV) disclose?

The form discloses a proposed sale of 355,161 common shares on 10/07/2025 with an aggregate market value of $5,734,289.35 and details of option exercises used to acquire those shares.

Who is selling the shares and through which broker for ROIV?

The filing lists sales by Eric Venker and the proposed sale is to be effected through Rockefeller Financial LLC at 45 Rockefeller Plaza, New York.

How many shares has the insider sold in the past three months for ROIV?

Reported sales total more than 1.99 million shares across multiple transactions between 07/21/2025 and 10/06/2025, with individual trades up to 683,818 shares.

How were the 355,161 shares acquired according to the filing?

All shares were acquired by exercise of options on 10/07/2025 with grant dates of 03/26/2020, 11/20/2017, and 04/20/2022.

What payment method was used to acquire the shares listed on the Form 144?

Payment was made by wire for the option exercises reported on 10/07/2025.

Does the filer assert any undisclosed material information?

The filer certifies they do not know any material adverse information regarding the issuer that has not been publicly disclosed.